Umecrine AB was founded in 2000 and is based on research performed at Umeå Neurosteroid Research Center, Umeå University, Sweden, showing that the negative effects of endogenous sex and stress hormones on the brain are possible to prevent. The negative effects are related to the influence of GABA steroids on the brain's main inhibiting system, the GABA system. The effect of Umecrine's patented and patent pending substances is to block the influence of GABA steroids on the GABAA receptor and thus preventing the GABA steroids from inducing negative CNS symptoms and disorders. The inventions represent unique and novel treatment principles with potential in several indication areas e.g. in the present case premenstrual disorders.